- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- intervenn.bio
- Total Funding
- $244.4M
- Last Round
- $201.0M Series CAug 2021
About
InterVenn Biosciences pioneers AI- and ML-powered glycoproteomic analysis through its GlycoVision platform, enabling high-throughput biomarker discovery from blood samples. Co-founded in 2017 by Nobel Laureate Carolyn Bertozzi, Dr. Carlito Lebrilla, and Aldo Carrascoso, the company serves biopharma partners and clinicians with diagnostic applications including GlycoKnow Ovarian for ovarian cancer detection.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account